Cuproptosis-Related lncRNAs are Biomarkers of Prognosis and Immune Microenvironment in Head and Neck Squamous Cell Carcinoma

• DOI: 10.3389/fgene.2022.947551
• Publication Date: 2022-07-22T11:25:11Z
• Authors: Liuqing Yang; Jinling Yu; Lu Tao; Handan Huang; Ying Gao; Jingjing Yao; Zhihui Liu
• Keywords: 0303 health sciences; 03 medical and health sciences; tumor mutational burden; lncRNA; cuproptosis; immune microenvironment; Genetics; QH426-470; head and neck squamous cell carcinoma; prognostic marker; 3. Good health

Background: Cuproptosis is a new type of cell death that induces protein toxic stress and eventually leads to death. Hence, regulating cuproptosis in tumor cells therapeutic approach. However, studies on cuproptosis-related long noncoding RNA (lncRNA) head neck squamous carcinoma (HNSC) have not been found. This study aimed explore the lncRNAs prognostic marker their relationship immune microenvironment HNSC by using bioinformatics methods. Methods: sequencing, genomic mutations, clinical data TCGA_HNSC were downloaded from The Cancer Genome Atlas. patients randomly assigned either training group or validation cohort. least absolute shrinkage selection operator Cox regression multivariate models used determine model cohort, its independent effect was further confirmed entire cohorts. Results: Based previous literature, we collected 19 genes associated with cuproptosis. Afterward, 783 obtained through coexpression. revealed constructed eight (AL132800.1, AC090587.1, AC079160.1, AC011462.4, AL157888.1, GRHL3-AS1, SNHG16, AC021148.2). Patients divided into high- low-risk groups based median risk score. Kaplan-Meier survival curve overall between statistically significant. receiver operating characteristic principal component analysis demonstrated accurate ability model. Univariate showed score an factor. In addition, establish nomogram predictive power markers. mutation burden significant differences groups. high-risk responded better immunotherapy than those group. We also found scores significantly drug sensitivity HNSC. Conclusion: summary, our identified cuprotosis-related signature as predictor, which may be promising biomarkers for predicting benefit well sensitivity.